Adjunct oral immunotherapy in patients with re-treated, multidrug-resistant or HIV-coinfected TB

Immunotherapy

Volumn 3, Issue 2, 2011, Pages 181-191

  Arjanova, Olga V ^a   Prihoda, Nathalia D ^a   Yurchenko, Larisa V ^a   Sokolenko, Nina I ^a   Frolov, Valery M ^b   Tarakanovskaya, Marina G ^c   Batdelger, Dendev ^d   Jirathitikal, Vichai ^a   Bourinbaiar, Aldar S ^e  

^a Lisichansk Regional Tuberculosis Dispensary ^*  (Thailand)

^b Lugansk State Medical University   (Ukraine)

^c Ekomed LLC   (Mongolia)

^d National Research Center for Infectious Diseases NRCID   (Mongolia)

^e Immunitor USA Inc   (United States)

Author keywords

DOT; extensively drug resistant; HIVTB; immunomodulator; multidrug resistant TB; Mycobacterium therapeutic vaccination

Indexed keywords

ETHAMBUTOL; HEMOGLOBIN; ISONIAZID; PLACEBO; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; UNCLASSIFIED DRUG; V5 IMMUNITOR; VACCINE;

ABSENCE OF SIDE EFFECTS; ADULT; ANEMIA; ARTICLE; BACTERIAL CLEARANCE; BODY TEMPERATURE; BODY WEIGHT; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; INFLAMMATION; LEUKOCYTE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTIDRUG RESISTANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SPUTUM; TUBERCULOSIS; WEIGHT GAIN;

ADMINISTRATION, ORAL; ADULT; ANTITUBERCULAR AGENTS; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY; MALE; TUBERCULOSIS;

EID: 79951748928     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.96     Document Type: Article

References (47)

1. Nunn P, Williams B, Floyd K, Dye C, Elzinga G, Raviglione M: Tuberculosis control in the era of HIV. Nat. Rev. Immunol. 5, 819-826 (2005). (Pubitemid 41400855)
2. Drobniewski F, Nikolayevsky V, Asmolov A, Bazhora Y, Servetsky S: Increasing trends in HIV and TB rates in Odessa and the Ukraine. Int. J. STD AIDS 16, 374-378 (2005). (Pubitemid 40704914)
3. Nikolayevskyy VV, Brown TJ, Bazhora YI, Asmolov AA, Balabanova YM, Drobniewski FA: Molecular epidemiology and prevalence of mutations conferring rifampicin and isoniazid resistance in Mycobacterium tuberculosis strains from the southern Ukraine. Clin. Microbiol. Infect. 13, 129-138 (2007). (Pubitemid 46111608)
4. Feshchenko II, Poddubnyi AF, Kunichkina SA, Antoniak SM: Pulmonary tuberculosis and acquired immunodeficiency syndrome in Ukraine (first communication). Probl. Tuberk. 4, 55-57 (1997).
5. van der Werf MJ, Yegorova OB, Chentsova N et al.: Tuberculosis-HIV coinfection in Kiev City, Ukraine. Emerg. Infect. Dis. 12, 766-768 (2006). (Pubitemid 43726850)
6. Raykhert I, Miskinis K, Lepshyna S et al.: HIV seroprevalence among new TB patients in the civilian and prisoner populations of Donetsk Oblast, Ukraine. Scand. J. Infect. Dis. 40, 655-662 (2008).
7. Small PM: Tuberculosis: a new vision for the 21st Century. Kekkaku 84, 721-726 (2009).
8. Churchyard GJ, Kaplan G, Fallows D, Wallis RS, Onyebujoh P, Rook GA: Advances in immunotherapy for tuberculosis treatment. Clin. Chest. Med. 30, 769-782 (2009).
9. Batdelger D, Dandii D, Jirathitikal V, Bourinbaiar AS: Open label trial of therapeutic hepatitis B vaccine V-5 Immunitor (V5) delivered by oral route. Lett. Drug Design Discovery 4, 540-544 (2007). (Pubitemid 350248370)
10. Batdelger D, Dandii D, Jirathitikal V, Bourinbaiar AS: Open label trial of therapeutic immunization with oral V-5 Immunitor (V5) vaccine in patients with chronic hepatitis C. Vaccine 26, 2733-2737 (2008).
11. Batdelger D, Dandii D, Dahgwahdorj YA et al.: Clinical experience with therapeutic vaccines designed for patients with hepatitis. Curr. Pharm. Design 15, 1159-1171 (2009).
12. Arjanova OV, Prihoda ND, Yurchenko LV et al.: Phase II trial of V-5 Immunitor (V5) in patients with chronic hepatitis C coinfected with HIV and Mycobacterium tuberculosis. J. Vaccin. Vaccinat. 1, 103 (2010).
13. Zaitzeva SI, Matveeva SL, Gerasimova TG et al.: Treatment of cavitary and infiltrating pulmonary tuberculosis with and without the immunomodulator Dzherelo. Clin. Microbiol. Infect. 15, 1154-1162 (2009).
14. Arjanova OV, Prihoda ND, Yurchenko LV et al.: Enhancement of efficacy of tuberculosis drugs with Immunoxel (Dzherelo) in HIV-infected patients with active pulmonary tuberculosis. Immunotherapy 1, 549-556 (2009).
15. Espinal MA, Kim SJ, Suarez PG et al.: Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in six countries. JAMA 283, 2537-2545 (2000). (Pubitemid 30324196)
16. Chan ED, Laurel V, Strand MJ et al.: Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 169, 1103-1109 (2004). (Pubitemid 38624789)
17. Fu Y, Chu NH, Yuan SL et al.: The effect of interventional therapy in multimodality treatment on multi-drug resistant pulmonary tuberculosis. Zhonghua Jie He He Huxi Za Zhi 31, 95-98 (2008).
18. Greinert U, Hillemann D, Lange C, Richter E: Antibiotic drug-resistant tuberculosis. Med. Klin. (Munich) 102, 957-966 (2007). (Pubitemid 350304532)
19. Ostrovskii VK, Asanov BM, Iangolenko DV: Some blood indices and the leukocytic index of intoxication in tuberculosis, pneumonias, abscesses, and cancer of the lung. Probl. Tuberk. Bolezn. Legk. 3, 43-46 (2005).
20. Ellner JJ: Immunoregulation in TB: observations and implications. Clin. Transl. Sci. 3, 23-28 (2010).
21. Das BS, Devi U, Mohan Rao C, Srivastava VK, Rath PK, Das BS: Effect of iron supplementation on mild to moderate anaemia in pulmonary tuberculosis. Br. J. Nutr. 90, 541-550 (2003). (Pubitemid 37168352)
22. Edwards LB, Livesay VT, Acquaviva FA, Palmer CE: Height, weight, tuberculous infection, and tuberculous disease. Arch. Environ. Health 22, 106-112 (1971).
23. Villamor E, Saathoff E, Mugusi F, Bosch RJ, Urassa W, Fawzi WW: Wasting and body composition of adults with pulmonary tuberculosis in relation to HIV-1 coinfection, socioeconomic status, and severity of tuberculosis. Eur. J. Clin. Nutr. 60, 163-171 (2006).
24. Kaufmann SH: Is the development of a new tuberculosis vaccine possible? Nat. Med. 6, 955-960 (2000).
25. Lei JP, Xiong GL, Hu QF, Li Y, Zong PL, Tu SH, Tu RY: Immunotherapeutic efficacy of BCG vaccine in pulmonary tuberculosis and its preventive effect on multidrug-resistant tuberculosis. Zhonghua Yu Fang Yixue Za Zhi 42, 86-89 (2008).
26. Radaeva TV, Nikonenko BV, Kapina MA, Mishchenko VV, Apt AS: Experimental approaches to designing vaccines against tuberculous infection reactivation. Probl. Tuberk. Bolezn. Legk. 5, 45-48 (2006).
27. Derrick SC, Perera LP, Dheenadhayalan V, Yang A, Kolibab K, Morris SL: The safety of postexposure vaccination of mice infected with Mycobacterium tuberculosis. Vaccine 26, 6092-6098 (2008).
28. Stanford J, Stanford C, Stansby G, Bottasso O, Bahr G, Grange J: The common mycobacterial antigens and their importance in the treatment of disease. Curr. Pharm. Des. 15, 1248-1260 (2009).
29. Luo Y, Lu S, Guo S: Immunotherapeutic effect of Mycobacteium vaccae on multi-drug resistant pulmonary tuberculosis. Zhonghua Jie He He Huxi Za Zhi 23, 85-88 (2000).
30. Vilaplana C, Montan E, Pinto S et al.: Double-blind, randomized, placebo-controlled Phase I clinical trial of the therapeutical antituberculous vaccine RUTI. Vaccine 28, 1106-1116 (2010).
31. Zhao G-R, Feng D-H: A systematic review of inactivated Mycobacterium phlei injection for adjunctive treatment of drug resistant pulmonary tuberculosis Pharm. J. Chin. PLA 25, 361-364 (2009).
32. Patel N, Trapathi SB: Improved cure rates in pulmonary tuberculosis category II (retreatment) with mycobacterium w. J. Indian Med. Assoc. 101, 680-682 (2003).
33. Tomioka H: Adjunctive immunotherapy of mycobacterial infections. Curr. Pharm. Des. 10, 3297-3312 (2004). (Pubitemid 39276617)
34. Prihoda ND, Arjanova OV, Yurchenko LV et al.: Open label trial of adjuvant immunotherapy with Dzherelo, Svitanok and Lizorm, in MDR TB, XDR-TB and TB/HIV coinfected patients receiving anti-tuberculosis therapy under DOT. J. Med. Plant Res. 1, 117-122 (2007).
35. Nikolaeva LG, Maystat TV, Pylypchuk VS, Volyanskii YuL, Masyuk LA, Kutsyna GA: Effect of oral immunomodulator Dzherelo (Immunoxel) in TB/HIV coinfected patients receiving anti-tuberculosis therapy under DOTS. Intl. Immunopharmacol. 8, 845-851 (2008).
36. Prihoda ND, Arjanova OV, Yurchenko LV et al.: Adjuvant immunotherapy of tuberculosis in drug-resistant TB and TB/HIV co-infected patients. Intl J. Biomed. Pharm. Sci. 2, 59-64 (2008).
37. Zaitzeva SI, Matveeva SL, Gerasimova TG et al.: Efficacy and safety of phytoconcentrate Dzherelo (Immunoxel) in treatment of patients with multi-drug resistant TB (MDR TB) in comparison to standard chemotherapy. Res. J. Med. Sci. 3, 36-41 (2009).
38. Arjanova OV, Prihoda ND, Sokolenko NI et al.: Impact of adjunct immunotherapy with multi-herbal supplement Dzherelo (Immunoxel) on treatment outcomes in end-stage TB/HIV patients. J. Antivir. Antiretrovir. 1, 86-88 (2009).
39. Prihoda ND, Arjanova OV, Yurchenko LV et al.: Adjuvant immunotherapy of extensively drug-resistant tuberculosis (XDR-TB) in Ukraine. Curr. Res. TB 1, 1-6 (2009).
40. Parida SK, Kaufmann SH: Novel tuberculosis vaccines on the horizon. Curr. Opin. Immunol. 22, 374-384 (2010).
41. Laurenzi M, Ginsberg A, Spigelman M: Challenges associated with current and future TB treatment. Infect. Disord. Drug Targets 7, 105-119 (2007). (Pubitemid 47103051)
42. Silin DS, Lyubomska OV, Jirathitikal V, Bourinbaiar AS: Oral vaccination: where we are? Expert. Opin. Drug Deliv. 4, 323-340 (2007). (Pubitemid 47260194)
43. Dlugovitzky D, Notario R, Martinel-Lamas D et al.: Immunotherapy with oral, heat-killed, Mycobacterium vaccae in patients with moderate to advanced pulmonary tuberculosis. Immunotherapy 2, 159-169 (2010).
44. Hanekom WA, Lawn SD, Dheda K, Whitelaw A: Tuberculosis research update. Trop. Med. Int. Health 15, 981-989 (2010).
45. Lahey T, Arbeit RD, Bakari M et al.: Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a Phase III study in Tanzania. Vaccine 28(48), 7652-7658 (2010).
46. Byrne ST, Denkin SM, Zhang Y: Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis. J. Antimicrob. Chemother. 59, 313-316 (2007). (Pubitemid 47072074)
47. Byrne ST, Denkin SM, Zhang Y: Aspirin antagonism in isoniazid treatment of tuberculosis in mice. Antimicrob. Agents Chemother. 51, 794-795 (2007). (Pubitemid 46185311)